Title : Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

Pub. Date : 2013

PMID : 24086526






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. Sorafenib signal transducer and activator of transcription 3 Homo sapiens
2 We found that sorafenib inhibits Jak/Stat3 signaling and downregulates their target genes, including cyclin D1, cyclin D2 and Mcl-1, in a dose-dependent manner. Sorafenib signal transducer and activator of transcription 3 Homo sapiens
3 Our findings demonstrate the involvement of the Jak2-Stat3-Mcl1 axis in response to sorafenib treatment, which may play a key role in sorafenib-mediated sensitization to Apo2L/TRAIL. Sorafenib signal transducer and activator of transcription 3 Homo sapiens
4 Our findings demonstrate the involvement of the Jak2-Stat3-Mcl1 axis in response to sorafenib treatment, which may play a key role in sorafenib-mediated sensitization to Apo2L/TRAIL. Sorafenib signal transducer and activator of transcription 3 Homo sapiens